About Paranta
About Paranta
Paranta Biosciences Limited is an unlisted Australian biopharmaceutical company developing PB01 as a first-in class biotherapeutic for the prevention of delayed graft function during kidney transplantation.
PB01, Paranta’s unique recombinant form of human follistatin-288, binds to and inhibits members of the TGF-β superfamily of cytokines, where it modulates the resulting inflammation, fibrosis and metabolic effects.
Paranta was established with the aim of commercializing property based on pioneering research by Monash University on follistatin. This initial research has been pivotal for Paranta's selection & subsequent clinical development of PB01. Paranta has advanced from the discovery to development phase and is now focused on acute kidney injury.
Paranta Biosciences has strong and active collaborative relationships with the Hudson Institute of Medical Research (previously Monash Institute of Medical Research), Monash University and affiliated medical and pharmaceutical institutes.
Paranta Team
The intellectual founding father of Paranta Biosciences who led the medical research team that first isolated follistatin and performed pioneering research on the structure, physiology and role of inhibins, activins and follistatin.
Professor David M. de Kretser